Usefulness of compounds with monacolin K in a case of statins intolerance
| Autor: | Ana Torres do Rego, Pablo Demelo-Rodríguez, Alejandro Parra-Virto, Jesús Millán Núñez-Cortés, Luis A. Álvarez-Sala |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Statin
medicine.drug_class Good control 030204 cardiovascular system & hematology Pharmacology Hyperlipoproteinemia Type II 03 medical and health sciences 0302 clinical medicine Ezetimibe Red yeast rice Humans Medicine Monacolin K Pharmacology (medical) In patient Lovastatin 030212 general & internal medicine PCSK9 Inhibitors General Environmental Science Secondary prevention Biological Products business.industry Anticholesteremic Agents General Engineering Cholesterol LDL Middle Aged General Earth and Planetary Sciences Drug Therapy Combination Female lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Clínica e Investigación en Arteriosclerosis (English Edition). 30:268-270 |
| ISSN: | 2529-9123 |
| DOI: | 10.1016/j.artere.2018.11.002 |
| Popis: | Many patients with familial hypercholesterolaemia (FH) or in secondary prevention situations and with statin intolerance do not achieve LDL-C targets, and require treatment with PCSK9 inhibitors (iPCSK9) and ezetimibe. The case is presented on a patient with FH and total intolerance to statins. Treatment with iPCSK9 and ezetimibe failed to achieve her LDL-C target. A compound with red yeast rice derivatives containing 3 mg of monacolin K was added, with good therapeutic compliance, and a very good control of LDL-C. The addition of red yeast rice derivatives containing low doses of monacolin K, together with IPCSK9 in patients with total intolerance to statins, may open a new path to obtain LDL-C targets in patients with high/very high cardiovascular risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect